SCHEMBL15580953

SCHEMBL15580953

C=C1c2ccccc2C(=O)N1c1nn(C(=O)OC(C)(C)C)c2cc(O[Si](C)(C)C(C)(C)C)ccc12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA9 Q16790 2/20 0.31
SMARCA2 P51531 1/20 0.31
SMARCA4 P51532 1/20 0.31
PBRM1 Q86U86 1/20 0.31
MAP2K4 P45985 1/20 0.30
CCNB2 O95067 1/20 0.30
CDK1 P06493 1/20 0.30
CCNB1 P14635 1/20 0.30
GSK3B P49841 1/20 0.30
CCNB3 Q8WWL7 1/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13736017 0.94 CA12 (0.34) MAPTHPGDSMN1; SMN2CA12CA1
SCHEMBL20402734 0.80 MAP2K4 (0.32) MAPTHPGDSMN1; SMN2SMARCA2SMARCA4
SCHEMBL18180085 0.76 CA12 (0.38) MAPTHPGDSMN1; SMN2CA12CA1
SCHEMBL13736944 0.75 PDGFRA (0.44) MAPTHPGDSMN1; SMN2CA12CA1
SCHEMBL15580945 0.74 CA12 (0.35) MAPTHPGDSMN1; SMN2CA12CA1
SCHEMBL24726042 0.73 RORC (0.33) SMN1; SMN2MAP2K4
SCHEMBL14737541 0.71 CA12 (0.39) CA12CA1CA9MAP2K4HSP90AA1
SCHEMBL18649379 0.70 RAB9A (0.39) SMN1; SMN2
SCHEMBL27907902 0.69 MAP2K4 (0.55) MAPTMAP2K4
SCHEMBL257418 0.68 RORC (0.34) MAP2K4PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9597317-B2 Substituted indazole derivatives active as kinase inhibitiors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-03-21 US disclosed
US-20160311776-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-10-27 US disclosed
US-20140080807-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080807-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K1, MAP3K20, MAP3K19 MAPT 2432/4885HPGD 1558/4885SMN1; SMN2 4479/4885
US-20160311776-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS MAP3K20, MAP3K1, MAP3K5 MAPT 2515/4885HPGD 1571/4885SMN1; SMN2 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.